Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 2/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240779 | 0.86 | ABCC9 (0.43) | ABCC9ABCC8KCNJ11KCNJ8CYP17A1 | |
| SCHEMBL628865 | 0.84 | MAPT (0.46) | ABCC9ABCC8KCNJ11KCNJ8CYP17A1 | |
| SCHEMBL30587156 | 0.84 | MAPT (0.46) | ABCC9ABCC8KCNJ11KCNJ8CYP17A1 | |
| SCHEMBL11959276 | 0.83 | LCK (0.49) | CYP17A1SMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29803307 | 0.81 | RXFP1 (0.55) | SMN1; SMN2RXFP1CISD2CA12CA1 | |
| SCHEMBL7667607 | 0.81 | RXFP1 (0.55) | SMN1; SMN2RXFP1CISD2CA12CA1 | |
| SCHEMBL8297312 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2TAS1R3TAS1R1TAS1R2CISD2 | |
| SCHEMBL6242548 | 0.80 | ABCC9 (0.42) | ABCC9ABCC8KCNJ11KCNJ8CYP17A1 | |
| SCHEMBL8292291 | 0.80 | KCNQ4 (0.48) | CYP17A1SMN1; SMN2CISD2CA12CA1 | |
| SCHEMBL6238138 | 0.78 | NPC1 (0.43) | CYP17A1SMN1; SMN2RXFP1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043011-A1 | Substituted benzanilide compound and noxious organism controlling agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1671941-A1 | SUBSTITUTED BENZANILIDE COMPOUND AND PEST CONTROL AGENT | Nissan Chemical Industries, Ltd. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20050250822-A1 | Substituted benzanilide compound and noxious organism controlling agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-11-10 | — | — | US | disclosed |
| EP-1538138-A1 | SUBSTITUTED BENZANILIDE COMPOUND AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043011-A1 | Substituted benzanilide compound and noxious organism controlling agent | L3MBTL1, L3MBTL3, L3MBTL4 | ABCC9 1758/4885ABCC8 1096/4885KCNJ11 1214/4885 |
| US-20050250822-A1 | Substituted benzanilide compound and noxious organism controlling agent | GCN1, L3MBTL3, L3MBTL4 | ABCC9 1010/4885ABCC8 947/4885KCNJ11 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.